Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PLTP | P55058 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6698972 | 0.93 | TRPV4 (0.34) | TRPV4PI4KBTP53PLTP | |
| Trifluoroacetic Acid SCHEMBL30480661 | 0.91 | TRPV4 (0.34) | TRPV4PI4KBTP53PLTP | |
| Trifluoroacetic Acid SCHEMBL226079 | 0.91 | TRPV4 (0.34) | TRPV4PI4KBTP53PLTP | |
| SCHEMBL29403637 | 0.90 | TRPV4 (0.36) | TRPV4PI4KBTP53PLTP | |
| SCHEMBL1008694 | 0.90 | TRPV4 (0.36) | TRPV4PI4KBTP53PLTP | |
| SCHEMBL7688594 | 0.89 | TRPV4 (0.34) | TRPV4PI4KBTP53PLTP | |
| Water SCHEMBL7685985 | 0.89 | TRPV4 (0.33) | TRPV4PI4KBTP53PLTP | |
| Diethylamine SCHEMBL7031731 | 0.87 | TRPV4 (0.34) | TRPV4PI4KBTP53PLTP | |
| SCHEMBL6700555 | 0.87 | TRPV4 (0.35) | TRPV4PI4KBPLTP | |
| Monoethanolamine SCHEMBL7032257 | 0.87 | TRPV4 (0.34) | TRPV4PI4KBTP53PLTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 379 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181673-A1 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | DIAPIN THERAPEUTICS LLC | 2023-06-15 | — | — | US | disclosed |
| EP-2847191-B1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-06-15 | — | — | EP | disclosed |
| EP-2771340-B1 | 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-04-13 | — | — | EP | disclosed |
| EP-2760862-B1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2015-10-21 | — | — | EP | disclosed |
| US-9156796-B2 | Benzoimidazole-carboxylic acid amide derivatives as APJ receptor modulators | SANOFI (FR) | 2015-10-13 | — | — | US | disclosed |
| US-9133181-B2 | Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-20150133432-A1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2015-05-14 | — | — | US | disclosed |
| US-9029400-B2 | 5-oxoisoxazoles as inhibitors of lipases and phospholipases | SANOFI (FR) | 2015-05-12 | — | — | US | disclosed |
| EP-2847191-A1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2015-03-18 | — | — | EP | disclosed |
| EP-2102198-B1 | SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| US-20040102518-A1 | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use | AVENTIS PHARMA AG (DE) | 2004-05-27 | — | — | US | disclosed |
| US-20040087659-A1 | Urea- and urethane-substituted acylureas, process for their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20040077716-A1 | Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| EP-1375508-A1 | N6-substituted adenosine analogues and their use as pharmaceutical agents | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030216370-A1 | Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-11-20 | — | — | US | disclosed |
| US-6624185-B2 | Drugs at least one lipid- or triglyceride-lowering active compound; and carriers for lipid metabolism | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-23 | — | — | US | disclosed |
| US-20030158094-A1 | Combination product of an aryl-substituted propanolamine derivative with at least one other active ingredient and the use of the product | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-21 | — | — | US | disclosed |
| US-20030158119-A1 | Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least on | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-21 | — | — | US | disclosed |
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-31 | — | — | US | disclosed |
| US-6380230-B1 | FOR THERAPY OF DYSKINESIA, OBESITY, IRRITABLE BOWEL SYNDROME, DISEASES WHOSE TREATMENT REQUIRES STIMULATION OF THE CHOLECYSTOKININ CCK-A RECEPTORS | SANOFI-SYNTHELABO (FR) | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102518-A1 | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use | SLC5A1, NQO1, SLC5A2 | TRPV4 2779/4885PI4KB 3176/4885TP53 4327/4885 |
| US-20040087659-A1 | Urea- and urethane-substituted acylureas, process for their preparation and their use | UGP2, UGDH, UGT1A1 | TRPV4 4378/4885PI4KB 3960/4885TP53 4040/4885 |
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | PNLIP, LIPC, APOB | TRPV4 3232/4885PI4KB 1178/4885TP53 4740/4885 |
| US-20150133432-A1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | MAP3K1, MAP3K6, MAP3K19 | TRPV4 1843/4885PI4KB 55/4885TP53 3434/4885 |
| US-20030158094-A1 | Combination product of an aryl-substituted propanolamine derivative with at least one other active ingredient and the use of the product | ADRA1D, ADRA1B, ADRB3 | TRPV4 505/4885PI4KB 3980/4885TP53 4822/4885 |
| US-20030216370-A1 | Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use | CPS1, AGPAT2, GLS | TRPV4 3466/4885PI4KB 3313/4885TP53 4455/4885 |
| US-20040077716-A1 | Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use | DPP4, CPS1, GLS | TRPV4 2376/4885PI4KB 1974/4885TP53 4392/4885 |
| US-20030158119-A1 | Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least on | SULT1E1, BPNT1, CYP3A4 | TRPV4 88/4885PI4KB 3395/4885TP53 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.